JTK-853

JTK-853 is a novel small molecule piperazine derivative that acts as a non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It binds to the palm site and β-hairpin region of the HCV polymerase, inhibiting viral replication. JTK-853 has demonstrated potent antiviral activity against genotype 1 HCV in vitro and in clinical studies, with a high genetic barrier to resistance. The drug has been evaluated in phase 1 clinical trials for hepatitis C virus infection and shows additive effects when combined with other direct antiviral agents such as nucleoside polymerase inhibitors, NS5A inhibitors, and protease inhibitors[1][2][3][5][7].

Other names

UNII-WDX8QQD13BUNII-WDX-8QQD13BUNII-WDX 8QQD13B(2R)-4-(5-cyclopropylthiazolo[4,5-d]pyrimidin-2-yl)-N-[3-fluoro-4-(trifluoromethoxy)benzyl]-1-[4-(trifluoromethyl)phenylsulfonyl]piperazine-2-carboxamide